ExodusPoint Capital Management LP purchased a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 281,795 shares of the company's stock, valued at approximately $826,000. ExodusPoint Capital Management LP owned 0.10% of AbCellera Biologics at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. DKM Wealth Management Inc. bought a new stake in AbCellera Biologics in the 4th quarter worth $29,000. State of New Jersey Common Pension Fund D purchased a new position in AbCellera Biologics during the 4th quarter valued at about $36,000. Diametric Capital LP bought a new position in AbCellera Biologics during the 4th quarter valued at approximately $53,000. IMG Wealth Management Inc. purchased a new stake in AbCellera Biologics in the 4th quarter worth approximately $56,000. Finally, Raymond James Financial Inc. bought a new stake in shares of AbCellera Biologics in the 4th quarter worth approximately $57,000. Institutional investors own 61.42% of the company's stock.
AbCellera Biologics Stock Performance
Shares of ABCL traded down $0.03 during mid-day trading on Tuesday, reaching $2.41. The company had a trading volume of 4,843,175 shares, compared to its average volume of 2,578,936. The firm has a 50-day moving average price of $2.56 and a 200 day moving average price of $2.77. AbCellera Biologics Inc. has a 52 week low of $1.89 and a 52 week high of $4.34. The company has a market capitalization of $718.15 million, a price-to-earnings ratio of -3.95 and a beta of 0.50.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. KeyCorp reduced their price objective on shares of AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Stifel Nicolaus lowered their target price on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, February 28th. Finally, Benchmark reiterated a "hold" rating on shares of AbCellera Biologics in a report on Monday, March 3rd.
Read Our Latest Stock Analysis on ABCL
AbCellera Biologics Profile
(
Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
See Also
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
